Corcept Therapeutics
NASDAQ: CORTIncorporated in Delaware · 2 known investors
Corcept develops cortisol modulators — molecules that regulate cortisol activity at the glucocorticoid receptor — to treat serious diseases across endocrinology, oncology, metabolism, and neurology. Its FDA-approved drug Korlym (mifepristone) treats hypercortisolism (Cushing syndrome), and the company has over 30 ongoing studies and more than 1,000 discovered proprietary cortisol modulators.
Investors · 2
Founder mafia
2 people who came through Corcept Therapeutics went on to found or lead other companies.
Competitors · 4
by search overlap
Seeking Alpha38 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
TipRanks31 shared keywordsFinancial analysis and stock research platform.
Robinhood28 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
StockTwits27 shared keywordsStocktwits is a social platform for investors and traders to share market news, discussions, sentiment polls, and live financial content. It aggregates breaking market news, equity coverage, and community discussions around individual stocks and crypto.
Companies competing with Corcept Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Corcept Therapeutics do?
- Corcept develops cortisol modulators — molecules that regulate cortisol activity at the glucocorticoid receptor — to treat serious diseases across endocrinology, oncology, metabolism, and neurology. Its FDA-approved drug Korlym (mifepristone) treats hypercortisolism (Cushing syndrome), and the company has over 30 ongoing studies and more than 1,000 discovered proprietary cortisol modulators.
- Who are Corcept Therapeutics's investors?
- Corcept Therapeutics's investors include Longitude Capital, Mountain Group Capital.